Form 4: MaxCyte Director John Johnston Executes Option and Sells Shares Under 10b5-1 Plan

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 28, 2024, John Johnston, a director of MaxCyte, Inc., exercised stock options to acquire 3,000 shares of common stock at a price of $2.926 per share.
• Simultaneously, Johnston sold 3,000 shares of MaxCyte common stock at a weighted average price of $3.722, with individual sales prices ranging from $3.70 to $3.74.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 19, 2023.
• Following these transactions, Johnston directly owns 141,950 shares of MaxCyte common stock and holds options for 1,396 shares.
• The stock option was fully vested and exercisable as of the transaction date.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-existing trading plan. There is no indication of positive or negative implications for the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• While the transactions are under a 10b5-1 plan, large sales by insiders can sometimes be perceived negatively by the market.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Insider transactions are common across publicly traded companies, and the reporting requirements are standardized by the SEC.
• The use of 10b5-1 trading plans is a widespread practice among corporate executives to manage their stock holdings while avoiding potential insider trading accusations.
• Comparable companies in the biotechnology sector, such as CRISPR Therapeutics or Editas Medicine, also see regular Form 4 filings from their directors and officers.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on stakeholders, as they are part of a pre-arranged trading plan and involve a relatively small number of shares.

Key Dates